Therapeutic considerations for disease progression in multiple sclerosis: Evidence, experience, and future expectations

Elliot M. Frohman, Olaf Stüve, Eva Havrdova, John Corboy, Anat Achiron, Robert Zivadinov, Per Soelberg Sorensen, J. Theodore Phillips, Brian G Weinshenker, Kathleen Hawker, Hans Peter Hartung, Lawrence Steinman, Scott Zamvil, Bruce A C Cree, Stephen Hauser, Howard Weiner, Michael K. Racke, Massimo Filippi

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

In the management of patients with multiple sclerosis (MS), providers are all faced with the highly formidable challenge of ascertaining whether, and to what degree, disease-modifying therapy is effective in the individual patient. While much has been learned in randomized, controlled clinical trials, we cannot simply extrapolate the outcomes of these initiatives and apply them to the care of a single patient. In the future, the application of pharmacogenetic techniques, proteomics, and microarray analysis will yield novel profiling information on individual patients that will substantially refine the specific therapeutic questions of relevance: (1) What is the best treatment for an individual patient? (2) Which patients require intensive therapeutic combination regimens to optimize control of the disease process? (3) What are the appropriate drug dosing targets for an individual patient? and (4) Which patients will be predisposed to the development of drug-related adverse events? Such data may provide a novel variable of drug responsiveness that will mandate its inclusion into the process of covariate analyses for clinical trials.

Original languageEnglish (US)
Pages (from-to)1519-1530
Number of pages12
JournalArchives of Neurology
Volume62
Issue number10
DOIs
StatePublished - Oct 2005

Fingerprint

Multiple Sclerosis
Disease Progression
Therapeutics
Progression
Pharmacogenetics
Microarray Analysis
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Proteomics
Randomized Controlled Trials
Clinical Trials
Drugs

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Frohman, E. M., Stüve, O., Havrdova, E., Corboy, J., Achiron, A., Zivadinov, R., ... Filippi, M. (2005). Therapeutic considerations for disease progression in multiple sclerosis: Evidence, experience, and future expectations. Archives of Neurology, 62(10), 1519-1530. https://doi.org/10.1001/archneur.62.10.1519

Therapeutic considerations for disease progression in multiple sclerosis : Evidence, experience, and future expectations. / Frohman, Elliot M.; Stüve, Olaf; Havrdova, Eva; Corboy, John; Achiron, Anat; Zivadinov, Robert; Sorensen, Per Soelberg; Phillips, J. Theodore; Weinshenker, Brian G; Hawker, Kathleen; Hartung, Hans Peter; Steinman, Lawrence; Zamvil, Scott; Cree, Bruce A C; Hauser, Stephen; Weiner, Howard; Racke, Michael K.; Filippi, Massimo.

In: Archives of Neurology, Vol. 62, No. 10, 10.2005, p. 1519-1530.

Research output: Contribution to journalArticle

Frohman, EM, Stüve, O, Havrdova, E, Corboy, J, Achiron, A, Zivadinov, R, Sorensen, PS, Phillips, JT, Weinshenker, BG, Hawker, K, Hartung, HP, Steinman, L, Zamvil, S, Cree, BAC, Hauser, S, Weiner, H, Racke, MK & Filippi, M 2005, 'Therapeutic considerations for disease progression in multiple sclerosis: Evidence, experience, and future expectations', Archives of Neurology, vol. 62, no. 10, pp. 1519-1530. https://doi.org/10.1001/archneur.62.10.1519
Frohman, Elliot M. ; Stüve, Olaf ; Havrdova, Eva ; Corboy, John ; Achiron, Anat ; Zivadinov, Robert ; Sorensen, Per Soelberg ; Phillips, J. Theodore ; Weinshenker, Brian G ; Hawker, Kathleen ; Hartung, Hans Peter ; Steinman, Lawrence ; Zamvil, Scott ; Cree, Bruce A C ; Hauser, Stephen ; Weiner, Howard ; Racke, Michael K. ; Filippi, Massimo. / Therapeutic considerations for disease progression in multiple sclerosis : Evidence, experience, and future expectations. In: Archives of Neurology. 2005 ; Vol. 62, No. 10. pp. 1519-1530.
@article{4d152dceddc94afb827ea943cf221b48,
title = "Therapeutic considerations for disease progression in multiple sclerosis: Evidence, experience, and future expectations",
abstract = "In the management of patients with multiple sclerosis (MS), providers are all faced with the highly formidable challenge of ascertaining whether, and to what degree, disease-modifying therapy is effective in the individual patient. While much has been learned in randomized, controlled clinical trials, we cannot simply extrapolate the outcomes of these initiatives and apply them to the care of a single patient. In the future, the application of pharmacogenetic techniques, proteomics, and microarray analysis will yield novel profiling information on individual patients that will substantially refine the specific therapeutic questions of relevance: (1) What is the best treatment for an individual patient? (2) Which patients require intensive therapeutic combination regimens to optimize control of the disease process? (3) What are the appropriate drug dosing targets for an individual patient? and (4) Which patients will be predisposed to the development of drug-related adverse events? Such data may provide a novel variable of drug responsiveness that will mandate its inclusion into the process of covariate analyses for clinical trials.",
author = "Frohman, {Elliot M.} and Olaf St{\"u}ve and Eva Havrdova and John Corboy and Anat Achiron and Robert Zivadinov and Sorensen, {Per Soelberg} and Phillips, {J. Theodore} and Weinshenker, {Brian G} and Kathleen Hawker and Hartung, {Hans Peter} and Lawrence Steinman and Scott Zamvil and Cree, {Bruce A C} and Stephen Hauser and Howard Weiner and Racke, {Michael K.} and Massimo Filippi",
year = "2005",
month = "10",
doi = "10.1001/archneur.62.10.1519",
language = "English (US)",
volume = "62",
pages = "1519--1530",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Therapeutic considerations for disease progression in multiple sclerosis

T2 - Evidence, experience, and future expectations

AU - Frohman, Elliot M.

AU - Stüve, Olaf

AU - Havrdova, Eva

AU - Corboy, John

AU - Achiron, Anat

AU - Zivadinov, Robert

AU - Sorensen, Per Soelberg

AU - Phillips, J. Theodore

AU - Weinshenker, Brian G

AU - Hawker, Kathleen

AU - Hartung, Hans Peter

AU - Steinman, Lawrence

AU - Zamvil, Scott

AU - Cree, Bruce A C

AU - Hauser, Stephen

AU - Weiner, Howard

AU - Racke, Michael K.

AU - Filippi, Massimo

PY - 2005/10

Y1 - 2005/10

N2 - In the management of patients with multiple sclerosis (MS), providers are all faced with the highly formidable challenge of ascertaining whether, and to what degree, disease-modifying therapy is effective in the individual patient. While much has been learned in randomized, controlled clinical trials, we cannot simply extrapolate the outcomes of these initiatives and apply them to the care of a single patient. In the future, the application of pharmacogenetic techniques, proteomics, and microarray analysis will yield novel profiling information on individual patients that will substantially refine the specific therapeutic questions of relevance: (1) What is the best treatment for an individual patient? (2) Which patients require intensive therapeutic combination regimens to optimize control of the disease process? (3) What are the appropriate drug dosing targets for an individual patient? and (4) Which patients will be predisposed to the development of drug-related adverse events? Such data may provide a novel variable of drug responsiveness that will mandate its inclusion into the process of covariate analyses for clinical trials.

AB - In the management of patients with multiple sclerosis (MS), providers are all faced with the highly formidable challenge of ascertaining whether, and to what degree, disease-modifying therapy is effective in the individual patient. While much has been learned in randomized, controlled clinical trials, we cannot simply extrapolate the outcomes of these initiatives and apply them to the care of a single patient. In the future, the application of pharmacogenetic techniques, proteomics, and microarray analysis will yield novel profiling information on individual patients that will substantially refine the specific therapeutic questions of relevance: (1) What is the best treatment for an individual patient? (2) Which patients require intensive therapeutic combination regimens to optimize control of the disease process? (3) What are the appropriate drug dosing targets for an individual patient? and (4) Which patients will be predisposed to the development of drug-related adverse events? Such data may provide a novel variable of drug responsiveness that will mandate its inclusion into the process of covariate analyses for clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=25144485958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144485958&partnerID=8YFLogxK

U2 - 10.1001/archneur.62.10.1519

DO - 10.1001/archneur.62.10.1519

M3 - Article

C2 - 16216934

AN - SCOPUS:25144485958

VL - 62

SP - 1519

EP - 1530

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 10

ER -